Date: 2014-03-07
Type of information: Private placement
Company: BiolineRx (Israel)
Investors:
Amount: $24.1 Million (€17.4 million)
Funding type: public offering of shares
Planned used:
Others: * On March 7, 2014, BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates ,has announced that it has closed its previously announced underwritten public offering of 9,660,000 American Depositary Shares (“ADSs”), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS, for gross proceeds of approximately $24.1 million. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional 1,260,000 ADSs purchased by the underwriters pursuant to the over-allotment option granted to them by BioLineRx. Roth Capital Partners acted as sole book-running manager for the offering. Maxim Group LLC acted as co-manager. The ADSs were issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC).
Therapeutic area:
